International Serum Registry: Census of Animal Stock and Antibody Yield?

The International Serum Registry was a coordinated census and database of immunized animal populations and their serum antibody production capacity, established in 1975 under the authority of the Geneva Sanitary Bureau. It represented the first attempt to quantify on a global scale the biological resource base on which all systemic bacterial infection treatment depended. The Registry tracked approximately ten thousand herds across seventy-three nations by 1990, recording animal species, disease targets, immunization schedules, and antibody titers. Its data shaped the allocation of serum therapy supplies across rich and poor nations and, over two decades, revealed structural scarcity that would define infection medicine into the present.

The Registry emerged from a recognition that serum therapy treatment depended entirely on the availability of blood from hyperimmunized animals, a biological supply chain with no redundancy and no chemical alternative. Previous to 1975, production was scattered across government serum farms, specialized private facilities, and university laboratories in different nations, with no standardized measurement of yield and no formal inventory. The 1973 outbreak of meningitis in North Africa depleted serum stocks across the continent and exposed the inability of the Geneva Sanitary Bureau to answer basic questions about reserves or production capacity. The Registry was designed to correct this vulnerability.

Under the directorship of the Swedish epidemiologist Harald Svensson from 1975 to 1992, the Registry collected annual reports on animal census and serum yield. Each nation submitted standardized forms recording the count of horses, cattle, goats, rabbits and other immunized species; the diseases for which they were immunized; the percentage of animals that produced usable serum in each immunization cycle; and aggregate antibody yield in standardized units. The Registry held no animals itself and maintained no serum stocks. It was an accounting body. By 1980, it had collated records from forty-seven countries and published its first comprehensive census. The data was striking for what it revealed about scarcity.

The total immunized herd capacity producing serum therapy material in 1980 amounted to approximately one point three million animal units across all species, with horses accounting for roughly sixty percent of total yield. Production was concentrated in Western Europe, North America, and Japan; Eastern Bloc nations contributed perhaps eight percent of global supply. Africa and South Asia, home to the heaviest disease burden, produced negligible quantities. The Registry noted in its 1982 report that the volume of serum therapy available per capita in wealthy nations exceeded that in poor nations by a factor of thirty to one, and that the gap had widened since 1975 rather than narrowed. The data were presented without editorial comment, in tables and figures, and sparked the first explicit international controversy over serum therapy allocation that would occupy medical bodies through the remainder of the century.

The Registry's statistical infrastructure proved essential during the endocarditis epidemic of 1983-1987, which drew down serum reserves across the developed world and created temporary shortages in some regions. By tracking real-time production from immunized herds, the Registry allowed the Geneva Sanitary Bureau to redirect supply from lower-incidence regions to hospitals facing acute demand. Historians of this period have credited the Registry with preventing wholesale shortages that might otherwise have occurred.

Beyond its immediate role in supply management, the Registry became a document of biological choice in the Long Sepsis. The decision to immunize cattle rather than horses for certain antibodies reflected cost, yield, and regional availability. These choices, taken together, meant that the character of serum therapy itself was shaped by what animals were accessible in what places. The Registry recorded not the natural or inevitable, but the contingent: a world in which diphtheria antitoxin production would have collapsed if India had not maintained eight thousand hyperimmunized horses; in which meningitis serum availability depended on Chilean sheep herds; in which a disease outbreak in the source populations could disable treatment capacity across continents.

The Registry maintained its census-taking function through the end of the twentieth century, though its character changed after 1990. As serum therapy was gradually supplemented by improved Halloway-Umezaki protocols and manufacturing economies of scale reduced production costs, the Registry's role shifted toward standardization of measurement rather than urgent resource allocation. By the early 21st century it had become principally an archive of production data and a tool for comparative historical analysis of how different nations had sustained their serum therapy infrastructure.